Current financial headlines

Sharemaestro Newsreel

Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.

Showing
37–72
Headlines
92
Sources here
3
Companies here
14
Current section Denmark financial news

Chronological news

Earlier headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading

European equities traded in the US as American depositary receipts were edging lower late Wednesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?

Novo Nordisk NVO stock has declined 4% over the past month, with the company's second-quarter 2026 results emerging as the primary factor behind the recent weakness. Although NVO beat earnings and revenue estimates, investors remained concerned about underlying growth trends in its core obesity …

NOVO-B main company
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?

Pfizer's PFE business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Vestas Wind Systems AS (VWDRY) (Q2 2026) Earnings Call Highlights: Revenue Surges 26% and ...

This article first appeared on GuruFocus. Revenue: EUR4.7 billion, an increase of 26% year-on-year, driven by strong growth in Power Solutions of 37%. EBIT Margin: 9.4%, a strong profitability improvement driven by both onshore and offshore. Earnings Per Share (EPS): EUR1.1 per share, growing …

VWS main company
Sharemaestro market context Price above Trend Line 52 weeks +55.6% VWS stored weekly price path from 15 Aug 2025 to 7 Aug 2026

H+H International AS (FRA:J0H) (Q2 2026) Earnings Call Highlights: Poland Drives 6% Organic ...

This article first appeared on GuruFocus. Release Date: August 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points H+H International AS (FRA:J0H) delivered 6% organic growth in Q2 2026, with a return to …

KBHL mentioned HH mentioned
Sharemaestro market context Price below Trend Line 52 weeks -16.2% · Next-week setup negative 36.4% KBHL stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Changes to full-year guidance for BioMar

Aktieselskabet Schouw & Co. Today, BioMar has released an announcement with updated guidance for the full year 2026. BioMar now expects revenue in the range of DKK 17-18 billion against previously DKK 16-17 billion and EBIT in the range of DKK 1,200-1,300 million compared …

SCHO mentioned
Sharemaestro market context Price below Trend Line 52 weeks +10.5% SCHO stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Novonesis launches Optiva® Triticum to help pasta manufacturers navigate wheat volatility without compromising quality

Novonesis (Novozymes A/S) COPENHAGEN, Denmark, August 12, 2026 – Novonesis today announced the launch of Optiva® Triticum, a new biosolution that helps pasta manufacturers increase flexibility in wheat sourcing while maintaining the texture, firmness and eating experience consumers expect. As fluctuations in durum wheat …

NSIS-B mentioned
Sharemaestro market context Trend signal active 52 weeks +3.4% NSIS-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026

[Latest] Global Microbial Biostimulants Market Size/Share Worth USD 13.88 Billion by 2034 at a 10.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Microbial Biostimulants Market size & share revenue was valued at approximately USD 5.10 Billion in 2024 and is expected to reach …

NSIS-B mentioned
Sharemaestro market context Trend signal active 52 weeks +3.4% NSIS-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Martela Corporation's Half Year Report 1 January - 30 June 2026

Martela Corporation Martela Corporation, Half year report, 12.8.2026, at 08:00 a.m. The revenue and operating result for January-June 2026 weakened compared to the same period of the previous year. April–June 2026 Revenue was EUR 14.5 million (24.6), representing a change of -41.0% Comparable operating …

KBHL mentioned
Sharemaestro market context Price below Trend Line 52 weeks -16.2% · Next-week setup negative 36.4% KBHL stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Martela lowers its 2026 revenue and result guidance

Martela Corporation Martela Corporation, Inside Information, 12.8.2026 at 07:40 a.m. Due to market uncertainty and weak demand, Martela lowers its full-year revenue and result guidance. The company estimates that its revenue for 2026 will amount to approximately EUR 66–73 million and that its comparable …

KBHL mentioned
Sharemaestro market context Price below Trend Line 52 weeks -16.2% · Next-week setup negative 36.4% KBHL stored weekly price path from 15 Aug 2025 to 7 Aug 2026

technotrans SE (WBO:TTR1) (Q2 2026) Earnings Call Highlights: Margin Resilience and Strategic ...

This article first appeared on GuruFocus. Revenue: EUR113.3 million in H1 2026, down 6% from EUR120.6 million in the prior year. EBIT: EUR8.0 million in H1 2026, compared to EUR8.4 million one year ago. EBIT Margin: Increased to 7.1% from 7.0% in the prior …

SCHO mentioned
Sharemaestro market context Price below Trend Line 52 weeks +10.5% SCHO stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Eli Lilly Scores Major Win in Weight-Loss Drug Race

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly's …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab A/S Company Announcement COPENHAGEN, Denmark; August 11, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,592 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of …

GMAB main company
Sharemaestro market context Price above Trend Line 52 weeks +33.5% GMAB stored weekly price path from 15 Aug 2025 to 7 Aug 2026

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

European equities traded in the US as American depositary receipts were tracking higher late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026

H+H International A/S: Interim Financial Report, H1 2026

Company announcement No. 10/2026 CHIEF EXECUTIVE OFFICER JÖRG BRINKMANN QUOTE COPENHAGEN, Denmark, Aug. 11, 2026 /PRNewswire/ -- "Following the severe winter weather in Q1, we delivered the expected normalization in Q2 and improved EBIT before special items to DKK 43 million. While market conditions …

HH main company
Sharemaestro market context Trend signal active 52 weeks -3.5% · Next-week setup negative 38.0% HH stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Lilly Takes Its Weight-Loss Pill Battle Overseas

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the developer of Foundayo and Zepbound, has received U.K. approval for Foundayo, the first approval for the weight-loss medication outside of the U.S. The The strategy pits Lilly directly against Novo Nordisk's …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026

REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?

The going has been strong for Regeneron Pharmaceuticals REGN over the past month. Shares of this biotech giant have surged 21.9% over the said time frame, outpacing the industry's growth of 4%. The stock has also outperformed the sector and the S&P 500 Index …

SCHO mentioned
Sharemaestro market context Price below Trend Line 52 weeks +10.5% SCHO stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?

The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Cloud AI Today - Novo Nordisk Partners With AWS For AI-Driven Drug Discovery

Novo Nordisk has entered a strategic partnership with Amazon Web Services (AWS) to enhance drug discovery using artificial intelligence and cloud technologies. This collaboration includes establishing a co-innovation hub in London, which brings together AWS engineers, AI specialists, and Novo Nordisk's research and development …

NOVO-B main company
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Alm. Brand A/S – Weekly report on share buybacks

Transactions during 4 August 2026 – 10 August 2026 On 7 May 2026, Alm. Brand A/S announced a share buy-back program of up to DKK 593 million, as described in company announcement no. 23/2026. The program is carried out in accordance with the Regulation …

ALMB main company
Sharemaestro market context Trend signal started 52 weeks -2.1% · Next-week setup positive 58.1% ALMB stored weekly price path from 15 Aug 2025 to 7 Aug 2026

NVO Crosses Above Average Analyst Target

In recent trading, shares of Novo-Nordisk AS (Symbol: NVO) have crossed above the average analyst 12-month target price of $47.48, changing hands for $47.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on …

NOVO-B main company
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026

BioHarvest Sciences Inc. (BHST) Reports Q2 Loss, Lags Revenue Estimates

BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items. This …

ZEAL mentioned
Sharemaestro market context Price above Trend Line 52 weeks -10.8% ZEAL stored weekly price path from 15 Aug 2025 to 7 Aug 2026

United Fintech enters its next chapter as infrastructure for wholesale finance

United Fintech Company establishes long-term partnership model and senior leadership team to support its next phase of growth London, Aug. 11, 2026 (GLOBE NEWSWIRE) -- United Fintech has appointed three new partners and established a senior leadership team, putting in place a long-term partnership …

DANSKE mentioned
Sharemaestro market context Trend signal active 52 weeks +51.0% · Next-week setup positive 57.2% DANSKE stored weekly price path from 15 Aug 2025 to 7 Aug 2026

ISS commences the second tranche of its share buyback programme including the announced increase by DKK 600 million

ISS A/S Company Announcement Copenhagen, 11 August 2026 No. 52/2026 ISS commences the second tranche of its share buyback programme including the announced increase by DKK 600 million ISS A/S, a leading workplace experience and facility management company, today announces that the Board of …

ISS mentioned
Sharemaestro market context Trend signal active 52 weeks +45.6% · Next-week setup positive 59.9% ISS stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Interim Report for 1 January – 30 June 2026

ISS A/S Company Announcement Copenhagen, 11 August 2026 No. 51/2026 Interim Report for 1 January – 30 June 2026 Continued improvement across all three KPIs in H1 2026 Highlights Financial performance On 19 May 2026, ISS and Deutsche Telekom AG (DTAG) announced a settlement …

ISS mentioned
Sharemaestro market context Trend signal active 52 weeks +45.6% · Next-week setup positive 59.9% ISS stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed

Tecan Group AG Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed Financial highlights – first half …

NKT mentioned
Sharemaestro market context Trend signal active 52 weeks +55.1% NKT stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America’s New Drug Manufacturing Policies?

For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conversation. With the U.S. government pushing pharmaceutical companies to manufacture more medicines domestically and …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.5 per share a year ago. These figures are adjusted for non-recurring items. …

ZEAL mentioned
Sharemaestro market context Price above Trend Line 52 weeks -10.8% ZEAL stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?

The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Hims Stock Falls on Earnings. Why a Guidance Hike Isn’t Enough.

Hims faces restructuring charges as it shifts its U.S. weight-loss business away from compounded GLP-1 medications. Continue Reading

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026

After massive Q1 loss, Maersk returns another service to Suez

After profits collapsed in the first quarter – and just days before it reports Q2 earnings – Maersk said it will return another headhaul service to the full Suez Canal-Red Sea route. "We are pleased to share that Maersk and Hapag-Lloyd are announcing a …

MAERSK-B mentioned
Sharemaestro market context Trend signal active 52 weeks +25.0% MAERSK-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026

European Stocks Close Mixed in Monday Trading as Investors Monitor Middle East War Developments

The European stock markets closed mixed in Monday trading as investors continue to gauge development PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Zealand Pharma - Transactions related to share buy-back program (week 32, 2026)

Zealand Pharma Company announcement No. 37 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 32, 2026) Copenhagen, Denmark, August 10, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future …

ZEAL main company
Sharemaestro market context Price above Trend Line 52 weeks -10.8% ZEAL stored weekly price path from 15 Aug 2025 to 7 Aug 2026

This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News.

New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes. Continue Reading

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock

Pfizer PFE stock has risen 6.9% since it announced second-quarter 2026 results on Aug. 4. Pfizer delivered a solid second quarter, beating estimates for both earnings and revenues. While earnings growth was flat year over year, revenues rose 1% on an operational basis. Strength …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026

ChemoMetec enters collaboration agreement with Roche Diagnostics

Chemometec A/S ANNOUNCEMENT NO. 311 After entering a Letter of Intent with Roche Diagnostics in February 2026, aiming to pursue a collaboration with the goal of creating synergies between the parties' solutions in the field of bioprocess monitoring, ChemoMetec and Roche Diagnostics have today …

CHEMM main company
Sharemaestro market context Price above Trend Line 52 weeks -13.3% CHEMM stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context